Table 7.
Univariate logistic regression analysis for determining potential risk factors of developing biliary stones post–LDLT (total n = 83).
| Variables | P–value | OR | 95% CI for OR |
|---|---|---|---|
| Age (years) | 0.964 | 1.001 | 0.948–1.057 |
| Sex (Male vs. Female) | 0.596 | 0.654 | 0.136–3.147 |
| BMI (Kg/m2) | 0.597 | 1.028 | 0.929–1.137 |
| CHILD score | 0.615 | 1.071 | 0.820–1.399 |
| MELD score | 0.489 | 1.043 | 0.926–1.174 |
| HCV | 0.039 | 2.788 | 1.051–7.400 |
| HCV/HCC | 0.170 | 0.477 | 0.166–1.373 |
| Diabetes Mellitus | 0.127 | 0.351 | 0.092–1.345 |
| Hypertension | 0.761 | 1.333 | 0.210–8.481 |
| Pre–transplant gall bladder stone | 0.468 | 1.500 | 0.501–4.488 |
| Hepatic artery anastomosis | 0.512 | 0.472 | 0.050–4.438 |
| Cold ischemia time (min) | 0.400 | 1.008 | 0.989–1.028 |
| Warm ischemia time (min) | 0.676 | 0.994 | 0.964–1.024 |
| Biliary drain (Yes vs. No) | 0.065 | 2.841 | 0.937–8.618 |
| Biliary leak (Yes vs. No) | 0.144 | 0.308 | 0.063–1.498 |
| Vascular complications (Yes vs. No) | 0.971 | 0.978 | 0.299–3.200 |
| Cytomegalovirus infection (Yes vs. No) | 0.585 | 0.628 | 0.118–3.335 |
| Acute rejection (Yes vs. No) | 0.039 | 4.727 | 1.084–20.618 |
| Chronic rejection (Yes vs. No) | 0.585 | 0.628 | 0.118–3.335 |
| Graft failure (Yes vs. No) | 0.999 | 0.000 | 0.000 – |
| Cholangitis (Yes vs. No) | 0.249 | 1.724 | 0.684–4.347 |
| Donor's age (years) | 0.933 | 1.003 | 0.936–1.075 |
| Donor's sex (Male vs. Female) | 0.066 | 0.359 | 0.121–1.070 |
| Donor's BMI (Kg/m2) | 0.019 | 1.251 | 1.038–1.509 |
| Degree of steatosis | 0.605 | 0.958 | 0.814–1.128 |
| No. of biliary ducts | |||
| 2 ducts vs. 1 duct | 0.065 | 2.683 | 0.941–7.652 |
| 3 ducts vs. 1 duct | 0.076 | 3.857 | 0.867–17.158 |
| No.of anastmosis (2 vs. 1) | 0.282 | 1.676 | 0.654–4.300 |
| Serum cholesterol | 0.038 | 1.010 | 1.001–1.019 |
| High density lipoprotein | 0.485 | 1.005 | 0.992–1.018 |
| Low density lipoprotein | 0.625 | 1.003 | 0.990–1.017 |
| Serum triglycerides | 0.125 | 1.009 | 0.998–1.020 |
| Calcineurin inhibitors | |||
| Cyclosporin vs. both | 0.740 | 1.524 | 0.127–18.324 |
| Tacrolimus vs. both | 0.769 | 0.688 | 0.057–8.344 |
| Mycophenolate mofetil (present vs. absent) | 0.392 | 0.671 | 0.269–1.674 |
| Everolimus (present vs. absent) | 0.539 | 1.354 | 0.515–3.563 |
BMI, body mass index; CI, confidence interval; HCC, hepatocellular cell carcinoma; HCV, hepatitis C virus; OR, odds ratio; significant at p < 0.05.